A few years back, the concept of altering genes to treat disease was considered science fiction. However, it is now a reality. Thanks to technological advancements, numerous other cutting-edge approaches are reshaping how we treat and cure diseases.
Cell therapy is one such approach that involves injecting new cells into a patient’s body to replace or repair damaged tissue to treat a disease. According to the report, a total of 1342 active cell-based therapy clinical trials have been identified and characterised based on cell type, target indication, and trial phase.
Nowadays, various medical organisations use cell therapies that are clinically approved. Based in Gosselies, Belgium, Bone Therapeutics is a biopharmaceutical company focused on innovative cell therapy products to treat bone diseases.
Secured €16M
Recently, the company secured a €16M loan from the European Investment Bank (EIB) to accelerate the clinical development of ALLOB, Bone Therapeutics’ scalable allogeneic cell therapy platform.